News | August 2, 2018

Aptinyx Initiates Phase 1 Study of NYX-458 Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies...

News | August 7, 2018

Rallybio Further Expands Drug Acquisition and Development Capabilities Rallybio Welcomes Laura Ekas, PhD and Eric Watsky, MD, Further Expanding Rallybio’s Drug Acquisition and Development Capabilities FARMINGTON, Connecticut, August 7, 2018 – Rallybio LLC, a...

News | August 6, 2018

Harpoon Therapeutics treats first patient with HPN424 in phase I clinical trial of metastatic castration-resistant prostate cancer (mCRPC) patients. HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical...

News | August 1, 2018

ReViral announces Series B investment ReViral announces US$55 million series B fundraising to advance RSV clinical studies London, UK – 1st August 2018: ReViral, an antiviral drug discovery and development company, focused on diseases caused by the Respiratory...
luctus Donec vulputate, felis libero elit. ante. velit,